Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.45 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (pericytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: norepinephrine, ergotamine tartrate, labetalol hydrochloride +54 | 1.00 |
| trials ClinicalTrials.gov | 50 Parkinson's trials, 7 stopped | 0.89 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 0428
Sealed predictions
- ADRA2B in dopamine neurons, braak-0.48 (p 0.195) → +0.08 (p 0.832)receipt 0434
Swarm cases
receipt 0434: ADRA2B in dopamine neurons, braak
- power
- full sample -0.24 (p 0.328, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.25 (p 0.323, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.35 (p 0.159, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.14, sign flips 0; without severely affected donors -0.24 (p 0.328, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADRA2B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts